Agent92260, I can't remember the post. If I did make such a error in phrasing a sentence it was a mistake in wording and not of the heart. A Buyback has always been my preferred method and there are many posts where I illustrate how shareholders and company both benefit. The company needs a loyal majority to stay onboard or new investors willing to see value as it climbs to new heights.
The R/S, fears, if not buried now would forever be the dark cloud making it impossible for a majority of shareholders at the base of the mountain willing to take that trip to its crest. An R/S presents zero value and offers no incentive for their loyalty to embark on that journey. We each would try to time a jump if there was a belief an R/S would diminish our share value. You are correct. Those shares need to be retired to have the greatest impact on shareholder confidence, value and loyalty for the company. It is the strongest message of reward to a shareholder; build the brand and line his pockets with gold he/she will be loyal.
This is the moment to cleanup the R/S issue forever. At these levels and at this moment in history the expense to do so is managements investment back into CBAI. That will definitely make this rise. Add in the recent AXM Pharma filings and it looks like we are preparing to make that major move very soon. Some investors believed years I have always stated months. This is a defining moment. Matt knows it and there is no coming back to go. The O/S has always been the elephant in the room and he has stated openly the board acknowledged it would be handled.
That statement was made a few months ago when a couple of iHub bloggers insisted hourly an R/S was coming. I was never in agreement with their beliefs and my rebuttal to all who insisted it would happen was simple:
"The insurance company at first funded the experiment with their own capital and determined it too risky and expensive to continue it privately. The political climate and uncertainty regarding the FDA and its handling of the science made the campaign to where sit comfortably now a long agonizing trip."
It has been floated on the backs of investors since and the risks we have been willing to endure. It is time to do right and reward the long risk takers and I have always said an R/S was not it.
I have presented proof of my findings daily regarding insurance trend data and UCB advancements to support the experiment was shifting to a curative based model in the U.S. Provided the FDA brightline rule a decision determing what worked best was declared. CBAI like other privates have finally won the decision: family-related works best. Billions spent on the efficacy and safety of UCBs along with healthcare money now pouring in only point towards a "success". CBAI with its bio insurance and new medical necessity models can only become more successful.
We win based on Matt's vision. If he and the Advisory Board didn't acknowledge the "delta" we would not be knocking on the door of "success" today. We would be a day late and a dollar short.
Thanks.
Market Data 
Markets 
AI
